I think hyperbole is your new speciality. B-OM met it's primary end piont and will probably meet or exceed it's secondary endpoints. Licensing deals soon enough.
Those with Cox jumped in then bailed on news. These short term traders are not holders in a science they know nothing about. IPIX successfully completed a Phase2 trial effectively proving it prevents OM in an extremely hard to treat disease. No question we will partner B after further compelling results.
Market Data 
Markets 
AI
